OA Dr. Maximilian J. Hochmair, Pneumologie, Krankenhaus Nord, Wien, über (neo)adjuvante Immuntherapie beim NSCLC, targeted therapies beim ALK- oder EGFR-positiven NSCLC, einen neuen Biomarker STK11 und Lurbinectidin beim SCLC.

Abstracts, die im Video diskutiert werden:

Kenmotsu H et al. Pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIA non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. Abstract 8501
Kwiatkowski DJ et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3). Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, Chicago, IL. Abstract 8503
Cascone T et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, Chicago, IL. Abstract 8504
Jimenez Aguilar E et al. Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%. Abstract 9111
Ahn MJ et al. Brigatinib (BRG) versus crizotinib (CRZ) in Asian versus non-Asian patients (pts) in the phase III ALTA-1L trial. Abstract 9026
Tsang Shaw A et al., Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC). Abstract 9019
Zhu C et al. Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. Abstract 9020
Paz-Ares LG et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. Abstract 8506

Bronchialkarzinom